Exact Sciences (EXAS)
(Delayed Data from NSDQ)
$69.80 USD
+0.87 (1.26%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $69.80 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value A Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$69.80 USD
+0.87 (1.26%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $69.80 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value A Growth F Momentum D VGM
Zacks News
Is Exact Sciences (EXAS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (EXAS) Outperforming Other Medical Stocks This Year?
Exact Sciences (EXAS) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
During Exact Sciences' (EXAS) third-quarter 2019 conference call, investor focus will be on the volume growth rate of its non-invasive screening test for colorectal cancer, Cologuard.
Exact Sciences (EXAS) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Exact Sciences (EXAS) closed at $96.47, marking a -0.94% move from the previous day.
Emergent's Chikungunya Vaccine Candidate Gets EMA's PRIME Tag
by Zacks Equity Research
Emergent's (EBS) chikungunya vaccine candidate CHIKV VLP gains the PRIME status from the Committee for Medicinal Products for Human Use in Europe.
Seattle Genetics Begins Phase III Study on Tucatinib Combo
by Zacks Equity Research
Seattle Genetics (SGEN) doses the first patient in the phase III HER2CLIMB-02 study on tucatinib in combination with Roche's Kadcyla for treating advanced/metastatic HER2-positive breast cancer.
bluebird Inks Genome Editing Research Deal With Novo Nordisk
by Zacks Equity Research
bluebird (BLUE) signs a collaboration contract with Novo Nordisk to develop next-generation in vivo genome editing therapies for the treatment of genetic disorders including hemophilia.
Seattle Genetics Up More Than 20% in 3 Months: Here's Why
by Zacks Equity Research
Seattle Genetics' (SGEN) only marketed product, Adcetris, has been performing well since its launch. The company's established pipeline candidates are also progressing well.
Has Exact Sciences (EXAS) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (EXAS) Outperforming Other Medical Stocks This Year?
Exact Sciences Corporation Enters Oversold Territory
by Zacks Equity Research
Exact Sciences Corporation has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Exact Sciences Gets FDA Nod for Label Expansion of Cologuard
by Zacks Equity Research
Exact Sciences (EXAS) gets FDA approval for use of its noninvasive colorectal cancer screening test, Cologuard, in eligible average-risk individuals aged 45 years or older.
Zacks Value Trader Highlights: Exact Sciences, Edwards Lifesciences, Bristol Myers-Squibb, Occidental Petroleum and Exxon Mobil
by Zacks Equity Research
Zacks Value Trader Highlights: Exact Sciences, Edwards Lifesciences, Bristol Myers-Squibb, Occidental Petroleum and Exxon Mobil
Stock Investors: Do You Need a Late Cycle Plan?
by Tracey Ryniec
The financial media keeps talking about the economy being in the late cycle but that doesn't mean you can't be buying stocks.
The Zacks Analyst Blog Highlights: Bristol-Myers Squibb Company, Celgene, Exact Sciences, Pfizer and Guardant Health
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bristol-Myers Squibb Company, Celgene, Exact Sciences, Pfizer and Guardant Health
3 Cancer Treatment Stocks to Enrich Your Portfolio
by Tirthankar Chakraborty
Investments in cancer therapies are expected to rise almost $250 billion by 2023, from $150 billion in 2018. Thus, companies that are coming up with innovative methods to cure this malaise are great investment choices.
Exact Sciences (EXAS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Exact Sciences (EXAS) delivered earnings and revenue surprises of 46.43% and 9.86%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Exact Sciences (EXAS) Q2 Earnings Expected to Decline
by Zacks Equity Research
Exact Sciences (EXAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights: Guardant, Illumina, Exact Sciences and Pfizer
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Guardant, Illumina, Exact Sciences and Pfizer
3 Stocks to Win Big in the Fight Against Cancer
by Tirthankar Chakraborty
We highlight three stocks that are using innovative ways to treat cancer, also called malignancy. These stocks are also great long-term investments.
The 5 Hottest Earnings Charts This Week
by Tracey Ryniec
These 5 stocks have had big rallies in 2019. Are they too hot to handle?
Earnings Preview: Exact Sciences (EXAS) Q1 Earnings Expected to Decline
by Zacks Equity Research
Exact Sciences (EXAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exact Sciences (EXAS) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
During Exact Sciences' (EXAS) first-quarter 2019 conference call, investor focus will be on the growth rate in the company's non-invasive screening test volume for colorectal cancer, Cologuard.
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
Zacks Market Edge Highlights: Edwards Lifesciences, Exact Sciences, Aimmune Therapeutics, Allergan and Evolus
by Zacks Equity Research
Zacks Market Edge Highlights: Edwards Lifesciences, Exact Sciences, Aimmune Therapeutics, Allergan and Evolus
NASH, Allergies and Beauty Stocks: Invest or Not?
by Tracey Ryniec
There's a lot of innovation going on at the biopharmaceutical companies but which areas should investors be targeting?
Exact Sciences (EXAS) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Exact Sciences (EXAS) delivered earnings and revenue surprises of 12.00% and -0.01%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?